

Abbreviations - 2021 Workshop Report

In this guide

[In this guide](#)

1. [COT FSA PBPK for Regulators Workshop Report 2021 - Cover page](#)
2. [Summary - COT FSA PBPK for Regulators Workshop Report 2021](#)
3. [Background - COT FSA PBPK for Regulators Workshop Report 2021](#)
4. [UK Food Standards Agency \(FSA\) requirement for PBPK modelling - 2021](#)
5. [Objectives and outline of the workshop - 2021](#)
6. [Questions put forward for the discussion sessions - 2021](#)
7. [Presentations and Panel discussions - 2021 Workshop report](#)
8. [Overarching conclusions - 2021 Workshop Report](#)
9. [Technical Terms - 2021 Workshop Report](#)
10. [Abbreviations - 2021 Workshop Report](#)
11. [References - 2021 Workshop Report](#)
12. [Organizing Committee, Committee Members and COT Secretariat - 2021 Workshop Report](#)

| | |
|------|---|
| ADME | Absorption, Distribution, Metabolism and Excretion |
| BfR | Bundesinstitut für Risikobewertung-The German Federal Institute for Risk Assessment |
| COT | Committee on Toxicity of Chemicals in Food, Consumer Products and the Environment |
| EFSA | European Food Standards Authority |
| EMA | European Medicines Agency |

| | |
|---------|--|
| FSA | Food Standards Agency |
| GSA | Global sensitivity analysis |
| INTEGRA | Integrated External and Internal Exposure |
| IPCS | International Programme on Chemical Safety |
| IVIVE | <i>In vitro</i> to <i>in vivo</i> extrapolation |
| JPMDA | Japanese Pharmaceuticals and Medical Devices Agency |
| MCSim | Monte Carlo Simulation |
| MoA | Mode of action |
| MoE | Margin of exposure |
| NAM | New approach methodology |
| NGRA | Next generation risk assessment |
| NLME | Non-linear mixed effects |
| NOAEL | No-observed adverse effect level |
| OECD | Organisation for Economic Co-operation and Development |
| PBPK | Physiologically based pharmacokinetic modelling |
| PFOA | Perfluorooctanesulfonic acid |

| | |
|---------|--|
| PFOS | Perfluorooctanoic acid |
| PK | Pharmacokinetics |
| PLETHEM | Population Life-course Exposure to Health Effects Model |
| POD | Point of departure |
| QIVIVE | Quantitative <i>in vitro</i> to <i>in vivo</i> extrapolation |
| SA | Sensitivity analysis |
| SCCS | Scientific Committee on Consumer Safety |
| SME | Small and medium-sized enterprises |
| TK | Toxicokinetics |
| UA | Uncertainty analysis |
| US EPA | United States Environmental Protection Agency |
| US FDA | United States Food and Drug Administration |
| WHO | World Health Organisation |